Evaluate the ability of a patient to produce antibody to a protein conjugated bacterial (H. influenza) vaccine to rule out antibody deficiency.
Quantitative Multiplex Bead Assay
New York DOH Approval Status
Serum separator tube. "Pre" and 30-day "post" Haemophilus influenzae b vaccination specimens should be submitted together for testing. "Post" specimen should be drawn 30 days after immunization and must be received within 60 days of "pre" specimen.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL) Mark specimens clearly as "Pre-Vaccine" or "Post-Vaccine".
Plasma or other body fluids. Contaminated, hemolyzed or, severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
< 1.0 µg/mL = Antibody concentration not protective.
≥ 1.0 µg/mL = Antibody to H. influenzae b detected. Suggestive of protection.
Responder status is determined according to the ratio of post-vaccination concentration to pre-vaccination concentration of Haemophilus influenza b antibody, IgG as follows:
1. If the post-vaccination concentration is less than 3.0 µg/mL, the patient is considered to be a nonresponder.
2. If the post-vaccination concentration is greater than or equal to 3.0 µg/mL, a patient with a ratio of greater than or equal to 4 is a good responder, a ratio of 2-4 is a weak responder, and a ratio of less than 2 is considered a nonresponder.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0050542||Haemophilus influenzae b Antibody, IgG||11256-5|
- H. influenzae Antibody
- Haemophilus influenzae b Vaccine Response
- HIB (Haemophilus influenzae Type B) Vaccine Response
- Vaccine Response